Trial Profile
Randomized, Phase II Trial of Intravenous Ascorbic Acid (Vitamin C) as an Adjunct to Pazopanib in the First-Line or Post-Immunotherapy Setting for Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (ccRCC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Ascorbic acid (Primary) ; Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 30 Apr 2021 Status changed from active, no longer recruiting to discontinued.
- 09 Apr 2021 Planned End Date changed from 1 Jun 2023 to 31 Dec 2021.
- 09 Apr 2021 Status changed from recruiting to active, no longer recruiting.